The table below shows Summit Therapeutics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$122.29M
-$61.17M
-$30.13M
-$13.13M
-$19.00M
-$20.67M
Capital expenditure
$245.00K
$422.00K
$4.00K
$53.00K
$361.00K
$39.00K
Investing cash flow
-$238.00K
$160.11M
$19.87M
-$645.06M
-$361.00K
-$39.00K
Dividends paid
-
-
-
SMMT operating cash flow (10-K history)
Summit Therapeutics Inc. reported operating cash flow of -$322.93M for fiscal year 2025. That is down 127.2% from -$142.11M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$21.50M (FY 2018) to -$322.93M. Figures come from the company's audited annual reports as filed with the SEC.
